

CLINICAL GUIDELINE

Hyperglycaemic Hyperosmolar State (HHS), guidance and care pathways

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	3
Does this version include changes to clinical advice:	No
Date Approved:	18 th April 2023
Date of Next Review:	1 st May 2026
Lead Author:	Steve Cleland
Approval Group:	Area Drug and Therapeutics Committee

Important Note:

The Intranet version of this document is the only version that is maintained.

Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

MANAGEMENT OF HYPERGLYCAEMIC HYPEROSMOLAR STATE (HHS)



This NHSGGC Guideline and Care Pathway has been based on the Joint British Diabetes Societies (Inpatient Care Group) Guideline (2012), available to download at:

Joint British Diabetes Societies (JBDS) for Inpatient Care Group | ABCD (Diabetes Care) Ltd

The complex pathophysiology and management of HHS means that **level 2 care** is usually most appropriate, with early input from specialist inpatient diabetes teams.

5 HEADLINE CONCEPTS:

(1) CORRECT DIAGNOSIS?

	HHS	Diabetic Ketoacidosis (DKA)
Age	Usually older	Usually younger
Volume depletion	10-20%	5-10%
Duration of onset	Days to weeks	Hours to days
Endogenous insulin	Usually present	Absent
Ketoacidosis	Absent / mild	Mild / moderate / severe

- HHS has slower onset than DKA, usually with no urgent need to clear ketoacidosis, and occurs in patients with brains at higher risk of injury by rapid shifts in sodium and glucose. Therefore, HHS requires <u>less</u> aggressive fluid resuscitation and glucose-lowering strategies than DKA
- Differentiating HHS from DKA is more problematic in context of severe intercurrent illness due to increased ketosis (eg SGLT2i, fasting ketosis) and non-ketotic metabolic acidosis (e.g. AKI). If predominant diagnosis unclear (HHS v DKA v both), then seek early specialist input to help tailor protocol to individual patient need.

(2) APPROPRIATE IV FLUIDS?

- Use intravenous (IV) **0.9%** sodium chloride to restore circulating volume and reverse dehydration (NB total body sodium is significantly deplete).
- Only switch to 0.45% sodium chloride solution if the osmolality is not declining (<3mOsm/kg/hour) despite adequate positive fluid balance.
- <u>An initial rise in sodium is expected (reversal of relative pseudohyponatraemia in context of hyperglycaemia) and is not itself an indication for hypotonic fluids.</u>
- The rate of fall of plasma sodium should not exceed 10 mmol/L in 24 hours.
- Aim for 2-3 litres positive balance by 6 hours and 3-6 litres positive balance by 12 hours.
- Consider less aggressive fluid resuscitation in context of low BMI (eg BMI<20), heart failure or oliguric renal failure.

(3) INSULIN – WHEN AND WHAT RATE?

- The fall in blood glucose should ideally be no more than 5 mmol/L/hour (so that serum osmolality doesn't fall too quickly). Low dose IV insulin <u>should only be commenced</u>
 - **<u>EITHER</u>** once the blood glucose level plateaus with IV fluids alone
 - **OR** immediately if there is significant ketosis (blood ketones > 1.5 or urine ketones greater than '+' (see Appendix A).

(4) TREATMENT TARGETS?

- If IV fluids and insulin are managed as above, serum osmolality should fall within the target range of 3-8mOsm/kg/hour.
- Ideally, laboratory-measured osmolality should be used, but calculated osmolality is adequate surrogate:
 2(Na⁺ + K⁺) + glucose + urea.
- Failure to achieve this target increases risk of neurological complications such as cerebral oedema and pontine myelinolysis.

(5) OTHER ISSUES?

Remember also to:

- (a) Correct other electrolyte deficiencies e.g. $[Mg^{++}]$, $[K^{+}]$, $[Ca^{++}]$, $[PO_4^{3-}]$
- (b) Prescribe prophylactic anticoagulation
- (c) Investigate for and treat intercurrent illness e.g. sepsis
- (d) Risk assess for pressure ulceration, especially in context of peripheral sensory neuropathy.

Date of birth: DD/MM/YYYY

CHI No:

Date:

(Or addressograph label)

Weight (kg):

Pregnancy



Default level of care = 2 (Medical High Dependency Unit), especially if any of these features:Osmolality >350mosm/kgSodium >160mmol/LH+ >80nmol/LHypo- or hyperkalaemiaSystolic BP <90mmHg</td>Heart rate >100 or <60bpm</td>Urine output <0.5ml/kg/hour</td>Creatinine >200µmol/LHypothermia

Step 1: Investigations

Time:

Other interventions to consider

Init

Other serious co-morbidity

	(initial when requested)	Initials
U&Es		
FBC		
Bicarbonate		
Venous blood	gas	
Ketones: Capill	ary (CBK) or Urine (UK)	
Laboratory (no	t capillary) blood glucose	•

Acute Coronary Syndrome or stroke

(initial il requested)	Initials
ECG or cardiac monitor	
Blood cultures	
CXR	
Record GCS	
MSSU	
Urinary catheter	

GCS <12

Step 2: Diagnosis for HHS	Record result	Criteria	
Laboratory glucose		More than 30mmol/L	
Calculate serum osmolality: 2 x (Na⁺+K⁺) + glucose + urea		More than 320mosm/kg	Consider DKA if ALL criteria not
Venous blood gas [H ⁺]		Less than 50nmol/L	met
Venous bicarbonate		More than 15mmol/L	
Ketones: Capillary Blood (CBK) or Urine (UK)		Less than 3mmol/L (less than 3+)	

Step 3: Immediate Management: 0-60 minutes	(Initial when complete)	Initials
Commence 1L sodium chloride 0.9% over 1hour (caution if heart failure) or faster if systolic B	<pre>> <90mmHg (see page 5)</pre>	
Only commence insulin if ketonaemia (>1.5mmol/L) or ketonuria (++ or more) (pg 6 and <u>APPEN</u> details)	DIX A for infusion rate	
Examine for source of sepsis or evidence of vascular event		
Mental state assessment (AMT 4 point)		
Ensure foot protection: 'Check / Protect / Refer' ('CPR') for feet		
Commence DVT prophylaxis (reduce enoxaparin dose to 20mg daily if <50kg or if eGFR<30ml/	min)	
Continue long acting insulin and withhold oral diabetes medications		

Step 4:	Ongoing Management: 60 minutes to 6 hours	(Initial when complete)	Initials			
Commence insulin at 0.05 units/kg/hour ONLY IF blood glucose level plateaus on IV fluids (pg 6 and APPENDIX A)						
Ensure hourly	CBG (capillary blood glucose). If CBG >28 or 'hi', use laboratory venous glucose. (record on page 11)				
Ensure U&Es,	laboratory glucose and osmolality measured at 2hours then 4hourly thereafter (re	ecord on page 11)				
Continue sodium chloride 0.9% at a rate of 0.5-1 L/hour depending on clinical status and improvement of osmolality						
Ensure appro	priate potassium replacement (see page 5)					
Once insulin o	commenced, commence IV Glucose 10% at a rate of 100mL/hour if glucose less the	an 14mmol/L (page 6)				

Step 5: Move to HHS Care Pathway 2 (page 7- STEP 6)

Date of birth: DD/MM/YYYY

CHI No:

(Or addressograph label)

A. Fluid and Potassium Prescription

Fluid Replacement	Potassium
	Replacement
• Aim to achieve 2-3L positive fluid balance by 6hours and avoid a fall in sodium >10mmol/L in 24hours	 Over 5.5mmol/L – no replacement
 Initial sodium rise expected. If sodium increasing but osmolality declining (by more than 	
3mosm/kg/hour) – CONTINUE sodium chloride 0.9%	• 3.5-5.5mmol/L – 40mmol replacement
 If sodium increasing AND osmolality INCREASING (or less than 3mosm/kg/hour 	(max rate
improvement), review fluid balance:	10mmol/hour)
• If inadequate fluid balance, CONSIDER increasing rate of infusion of sodium chloride 0.9%	
• If adequate fluid balance, CONSIDER switching to sodium chloride 0.45% at same rate	 Below 3.5mmol/L – senior review as
 If osmolality falling at more than 8mOsm/kg/hour CONSIDER reducing infusion rate of IV fluids and/or insulin if commenced. 	additional potassium required

	PR	ESCRIPTION: INTRAV	ENOUS FL	UIDS/POT/	ASSIUM		A	DMINIS	STRATIC	ON
Date	Time	Name of fluid	Vol (ml)	Duration	Signature, PRINTED	Comment	Infusion	started:	Given	Check
		Name of additive	Dose		name and designation		Date	Time	by	by
		Sodium chloride 0.9%	500ml							
				30mins						
		Sodium chloride 0.9%	500ml							
				30mins						
		Sodium chloride 0.9%	500ml							
		Sodium chloride 0.9%	500ml							
		Sodium chloride 0.9%	500ml							
			500111							
		Sodium chloride 0.9%	500							
			500ml							
		Sodium chloride 0.9%								
		Sourum chioride 0.9%	500ml							
		Sodium chloride 0.9%	500ml							
		Sodium chloride 0.9%	500ml							
STOPP	ED DATE	STOPPED	BY (Prescribe	er's signature,	PRINTED name and des	signation):	•	•	·	·

Fluid prescription chart continues on page 6

Hyperglycaemic Hyperosmolar State (HHS) Care Pathway **1**: Prescribing

Date of birth: DD/MM/YYYY

CHI NO: (Or addressograph label)

Hyperglycaemic Hyperosmolar State (HHS) Care Pathway **1**: Prescribing (cont'd)

	PRESCRIPTION: INTRAVENOUS FLUIDS/POTASSIUM							ADMINIS	STRATION	1
Date	Time	Name of fluid	Vol (ml) Duration	Duration	Signature, PRINTED	Comment	Infusion	started:	Given	Check
		Name of additive	Dose		name and designation		Date	Time	by	by
STOP	STOPPED DATE: STOPPED BY (Prescriber's signature, PRINTED name and designation):									

After 6 hours move to HHS Care Pathway 2: Prescribing (page 8)

B. Intravenous (IV) Insulin Prescription

- Commence IV insulin ONLY IF blood glucose level plateaus on IV fluids or if significantly ketonaemic (see <u>APPENDIX A</u> for infusion rate details)
- Prescribe and administer insulin using the chart on pages 9 and 10. Prescribe 'As per chart' on Kardex.

C. IV Glucose 10% Prescription

Only for patients on IV insulin with blood glucose < 14mmol/L, CONTINUE sodium chloride 0.9%

If blood glucose rises to >15mmol/L: increase insulin rate by 1 unit per hour (with or without glucose 10%) to maintain a blood glucose target of 10-15mmol/L

		PRESCRIPTION	: INTRAVENOUS	GLUCOSE 10	%			ADMINIS	STRATION	1
Date	Time	Name of fluid	Vol (ml)	Duration	Signature, PRINTED	Comment	Infusion	started:	Given	Check
					name and designation		Date	Time	by	by
		Glucose 10%	500ml	5 hours						
		Glucose 10%	500ml	5 hours						
STOPP	TOPPED DATE: STOPPED BY (Prescriber's signature, PRINTED name and designation):									

Date of birth:	DD/MM/YYYY
----------------	------------

CHI No:

(Or addressograph label)

STEP 6 Refer to inpatient diabetes team at the earliest opportunity

STEP 7 Read principles of treatment below

- HHS is associated with a significantly higher morbidity and mortality than DKA and must be managed intensively
- Fluid losses are estimated to be 10-22L in a person weighing 100kg
- Rate of fall of sodium should not exceed 10mmol/L in 24hours
- Complete normalisation of biochemistry, including other electrolyte deficiencies, may take 72hours
- Patients with HHS have a significantly higher risk of thromboembolism than in DKA and therefore all patients should receive prophylactic low molecular weight heparin (LMWH) for the duration of admission unless contra-indicated

Hyperglycaemic Hyperosmolar State (HHS):

Care Pathway **2**

• There is also a high risk of pressure ulceration

STEP 8	Ongoing Management: 6-12hours	(initial when complete)	Initials
Continue 4	hourly monitoring blood glucose, sodium, calculated osmolality and fluid balan	ce (see table 1, record on p11)	
Assess for a	omplications of treatment i.e. fluid overload, cerebral oedema, deteriorating co	onscious level	
Continue tr	eatment of underlying cause, and replace other electrolyte deficiencies: [K $^{\scriptscriptstyle +}$], [N	Иg ⁺⁺], [Ca ⁺⁺], [PO ₄ ³⁻]	
Aim to kee	blood glucose 10-15mmol/L		
Continue IN	fluid replacement (see table 2 below and page 8 for prescribing chart)		

STEP 9	Ongoing Management: 12hours to resolution	(initial when complete)	Initials			
Continue IV fluid replacement (see table 2) aiming to achieve replacement of estimated fluid losses within next 12 hours depending on initial degree of dehydration / body weight and MOST IMPORTANTLY response to treatment						
Continue keeping blood glucose 10-15mmol/L and adjust insulin infusion as appropriate (see table 1)						
Continue m	onitoring sodium (see table 1)					

Table 1: Reference Targets for HHS Management (6 hours to resolution)

Time	6hour	12hour	24hour	48hour	>48hour						
	Improvement less	Not more than	Not more than	Not more than	Not more than						
Sodium	than 5mmol/L	5mmol/L	10mmol/L	20mmol/L	10mmol/L						
		improvement	improvement	improvement	improvement/day						
Osmolality	18-42mosm/kg	36-96mosm/kg	Continued	Continued							
	improvement	improvement	improvement	improvement							
			towards normal	towards normal							
Insulin	Commer	nce if blood glucose leve	el plateaus on IV fluids o	r significant ketonaemia	(APPENDIX A)						
		Reduce insulin rate if	osmolality decreasing b	y more than 8mosm/kg/	hour						
Fluid	2-3L positive	3-6L positive	Aim to replace remai	ning estimated losses	Neutral balance						
balance	balance	balance	·								
Other	Ensure LMWH prescribed, pressure care, electrolyte correction, continuation of (appropriate) diabetes medications										

Table 2: IV Fluid and Potassium Replacement (prescribing chart on page 8)

Fluid Replacement	Potassium Replacement - first 24hours	Potassium Replacement > 24 hours
 Continue IV fluid replacement to achieve positive fluid balance of 3-6L by 12hours Beyond 12hours, aim for IV fluid replacement aiming for replacement of estimated fluid losses over next 12 hours – dependent on initial degree of dehydration and response of treatment so far Continue IV fluids thereafter until eating and drinking normally 	 Over 5.5mmol/L – no replacement 3.5-5.5mmol/L – 40mmol replacement (max rate 10mmol/hour) Below 3.5mmol/L – senior review as additional potassium required 	 Over 5.5mmol/L – no replacement 3.5-5.5mmol/L – 10mmol replacement Below 3.5mmol/L – 20mmol replacement

CHI NO: (Or addressograph label)

Hyperglycaemic Hyperosmolar State (HHS) Care Pathway **2**: Prescribing

A. Fluid and Potassium Prescription (see table 2 on page 7)

PRESCRIPTION: INTRAVENOUS FLUIDS/POTASSIUM Date Time Name of fluid Vol (ml) Duration Signature, PRINTED Column Col							ADMINISTRATION					
Time	Name of fluid	Vol (ml)	Duration	Signature, PRINTED	Comment	Infusion	started:	Given	Check			
	Name of additive	Dose		name and designation		Date	Time	by	by			
ED DATI				e, PRINTED name and de								
		Time Name of fluid Name of additive Image: Additite Image: Additive<	TimeName of fluidVol (ml)Name of additiveDoseImage: Image: Imag	Time Name of fluid Name of additiveVol (ml) DoseDurationName of additiveDoseInternational <br< td=""><td>Time Name of fluid Vol (ml) Duration Signature, PRINTED name and designation Name of additive Dose Income In</td><td>Time Name of fluid Vol (ml) Duration Signature, PRINTED name and designation Comment designation Name of additive Dose Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation <</td><td>Name of fluid Vol (m) Duration Signature, PRINTED name and designation Infusion Name of additive Dose Comment name and designation Dote Dote Image of additive Dose Image and designation Image and designation Dote Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation<</td><td>Name of fluid Name of additive Vol (m) Dose Duration ame and designation Signature, PRINTED name and designation Comment designation Influion-stretce: Date Image: Signature, PRINTED ame and designation Image: Signature, PRINTED name and designation Image: Signature, PRINTED designation Image: Signature, PRINTED designature, PRINTED designature, PRINTED designature</td><td>Name of fluid Vol (ml) Duration mame and designation Industrates in the second designation</td></br<>	Time Name of fluid Vol (ml) Duration Signature, PRINTED name and designation Name of additive Dose Income In	Time Name of fluid Vol (ml) Duration Signature, PRINTED name and designation Comment designation Name of additive Dose Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation <	Name of fluid Vol (m) Duration Signature, PRINTED name and designation Infusion Name of additive Dose Comment name and designation Dote Dote Image of additive Dose Image and designation Image and designation Dote Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation Image and designation Image and designation Image of additive Image and designation Image and designation<	Name of fluid Name of additive Vol (m) Dose Duration ame and designation Signature, PRINTED name and designation Comment designation Influion-stretce: Date Image: Signature, PRINTED ame and designation Image: Signature, PRINTED name and designation Image: Signature, PRINTED designation Image: Signature, PRINTED designature, PRINTED designature, PRINTED designature	Name of fluid Vol (ml) Duration mame and designation Industrates in the second designation			

B. Intravenous Insulin Prescription (see table 1 on page 7 for guidance)

C. Glucose 10% Prescription

Only for patients on IV insulin with blood glucose < 14mmol/L, CONTINUE sodium chloride 0.9%

** If blood glucose rises to >15mmol/L: increase insulin rate by 1 unit per hour (with or without glucose 10%) to maintain a blood glucose target of 10-15mmol/L **

			ADMINIS	TRATIO	4			
Name of fluid	Vol (ml)	Duration	Signature, PRINTED name	Comment	Infusion	started:	Given	Check
			and designation		Date	Time	by	by
Glucose 10%	500ml	5 hours						
Glucose 10%	500ml	5 hours						
<u> </u>	Glucose 10%	Glucose 10% 500ml	Glucose 10% 500ml 5 hours	Glucose 10% 500ml 5 hours	Glucose 10% 500ml 5 hours	Glucose 10% 500ml 5 hours Date	Glucose 10% 500ml 5 hours Date Time	Glucose 10% 500ml 5 hours Date Time by

Date of birth: DD/MM/YYYY

CHI No: (Or addressograph label) Hyperglycaemic Hyperosmolar State: Intravenous insulin

Prescription, administration and monitoring chart

** ONLY START IF BLOOD GLUCOSE LEVEL PLATEAUS OR IF KETONAEMIC — SEE APPENDIX A **

L Pre Medicine	scription	-	amount of insu	l'an	Name of	ماناب مسغ	Total volume	Insulin	Route	Prescriber's si	an at una l					
healcine		in syri		IIN	Name of	anuent	in syringe	concentration	Route	and designation		RINTED	name			
	E INSULIN or Humulin S [®]	J	50 units		Sodiun Chloric	n le 0.9%	50ml	1 unit/ml	IV							
2 Insi	lin flow	rate dei	ails											<u> </u>		
. msc	Date	Start	Insulin dose	Re	quired	Additiona	linstructions	Prescriber's signatu	'e	3 Prep	ř			et up de	1	
	Dutt	time	(SEE APPENDIX	flc s	ow rate etting	, autorio		PRINTED name and designation	-		Date	Time	and	paration d pump t up by	Volume in syringe/bag (Post-priming)	Checke by
Com			A)		l/hour)	uide en eien	:f:t loctore			Initial						
nitial	mence if b	lood gluc	ose level plat	eaus		ulds or sigr	lificant Ketona	aemia – see APPENDIX /	4	prep						
ate										Repeat 1						
	R	educe rat	e if serum osr	nolali	ity decrea	asing at mo	ore than 8mos	m/kg/hour		Repeat 2						
Change 1										-						
Change 2										Repeat 3						
Change 3										Repeat 4						
Change 4																
_																
							by nursing								-	
Date	Time	Volume remaining (ml)	Total volu cu	ıme in ımulat			ne infused last check (ml)	Blood glucose reading (finger prick) mmol/L		flow rate prescribe section 2 above) ml/hour	ed Se	tby	Checked by	Site check (tick)	Comn	nents
							. /			•						

Date of birth: DD/MM/YYYY

CHI No: (Or addressograph label) Hyperglycaemic Hyperosmolar State: Intravenous insulin

Prescription, administration and monitoring chart

******ONLY START IF BLOOD GLUCOSE LEVEL PLATEAUS OR IF KETONAEMIC — SEE APPENDIX A

4 Ac	ministr	ation details	- continued (to be com	pleted ONE hour	ly by nursing staff)					
Date	Time	Volume remaining (ml)	Total volume infused (ml): cumulative	Volume infused since last check (ml)	Blood glucose reading (finger prick) mmol/L	Insulin flow rate prescribed (see section 2 above) ml/hour	Set by	Checked by	Site check (tick)	Comments
5. Dis	continua	ation*								
Prescrib	er's signati	ure. PRINTED nai	me and designation:		Date:	Time:				

Switch to appropriate s/c insulin when patient is eating, drinking and biochemical abnormalities have resolved. This should be done whenever practical following discussion with the diabetes team. Occasionally, if previously well controlled on oral agents or new presentation of diabetes, it may be appropriate to try oral agents.

Monitoring Record:

Aim: to reduce osmolality by 3-8mosm/kg/hour

A: First 24 hours (See section C for ketones)

(Or addressograph label)

Time (hours)	0	2	6	10	14	18	22
Actual sample time							
Lab Glucose [*] (mmol/L)							
Sodium (mmol/L)							
Potassium (mmol/L)							
Urea (mmol/L)							
Creatinine (micromol/L)							
Osmolality (mosm/Kg)							
H ⁺ (nmol/L) **							
*	• • • •		ا ماد ماد	···+• •	e		

*Record finger prick blood glucose in the table below

******[H⁺] - frequency of monitoring may differ to table

Page **11** of **12**

	Ca	pillary blood	l gluco	se in mm	ol/L:che	eck ho	ourly	(lab ven	ous glucos	se if CBO	G>2	8 or 'hi')	
	Time	Result		Time	Result			Time	Result			Time	Result
S			S				S				S		
uno			uno				Ino				Ino		
6 h			5 PC				8 h				4 h		
rst			7-12				3-1				9-2		
Fir							1				1		
]] [

B: After 24 hours

Date					
Actual sample time					
Lab Glucose (mmol/L)					
CBG (mmol/L)					
Sodium (mmol/L)					
Potassium (mmol/L)					
Urea (mmol/L)					
Creatinine (micromol/L)					
Osmolality (mosm/Kg)					
H ⁺ (nmol/L)					

C: Ketone monitoring

Capillary blood KETONES (CBK) in mmol/L														
Date	Time	Result	Date	Time	Result	Date	Time	Result	Date	Time	Result	Date	Time	Result

Name:

CHI No:

Date of birth:

Appendix A: When and how to start fixed-rate intravenous insulin infusions (FRIII) in HHS

Scenario 1 – HHS and CBK <1.5 (UK – or +)

- Do not start FRIII immediately
- Continue to monitor BG during IV fluid replacement (use laboratory venous BG if CBG '>28' or 'hi')
- If BG plateaus, commence FRIII at rate of 0.05 units/kg/hr (correct to nearest whole unit), aiming for target CBG 10-15

Scenario 2 – HHS and CBK \geq 1.5 (UK >+) and [H⁺] <50

- Start FRIII immediately at rate of 0.05 units/kg/hr (correct to nearest whole unit)
- Repeat BG (use laboratory venous BG if CBG '>28' or 'hi') and CBK at hourly intervals
- If BG decreasing too quickly (> 5mmol/l/hr), reduce FRIII rate by 50%
- Repeat BG and CBK regularly and, if necessary, adjust insulin rate to ensure both ketones are clearing and glucose is falling in a controlled manner, aiming for target CBG 10-15

Scenario 3 – HHS and CBK \geq 1.5 (UK >+) and [H⁺] \geq 50

- <u>Start FRIII immediately at rate of 6 units/hr</u> (or 0.05 units/kg/hr, if weight >120kg correct to nearest whole unit)
- Continue to monitor BG, CBK and [H⁺] regularly and adjust insulin rate as required (be guided by insulin adjustment principles from the 'DKA protocol'), aiming for target CBG 10-15

IF IN DOUBT, SEEK URGENT INPUT FROM THE DIABETES TEAM

Abbreviations

- HHS Hyperglycaemic Hyperosmolar State
- FRIII Fixed-rate intravenous insulin infusion
- BG Blood Glucose
- CBG Capillary Blood Glucose level
- CBK Capillary Blood Ketone level
- UK Urinary Ketone level
- [H+] Hydrogen Ion level from venous or arterial blood gas analysis
- DKA Diabetic ketoacidosis